ESSA Pharmaceuticals
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC (NCT05075577) | ESSA Pharmaceuticals | 2021-12-21 |
| Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer (NCT04421222) | ESSA Pharmaceuticals | 2020-06-23 |
Track ESSA Pharmaceuticals automatically
Every clearance here is in the API, with alerts when new ones post.